Analyst Comment
Bioretec seeks additional savings through change negotiations
Summary
- Bioretec announced new change negotiations in its Finnish production to enhance operational efficiency and improve profitability, potentially affecting up to four employees.
- The company aims for additional annual savings of 0.2 MEUR, adding to a previous savings target of 0.4 MEUR, due to oversized production capacity relative to current demand.
- Investments in production were made anticipating faster sales growth of the RemeOs product family, but market adoption has been slower than expected.
- The company is adjusting its cost structure to align with actual demand and protect cash reserves raised through a recent share issue.
This content is generated by AI. You can give feedback on it in the Inderes forum.
Translation: Original published in Finnish on 6/2/2026 at 8:11 am EEST.
Bioretec announced on Monday evening that it will initiate new change negotiations in its Finnish production to enhance operational efficiency and improve profitability. The negotiations concern 12 people, and potential measures, including terminations of employment, affect a maximum of four people. The company aims for estimated additional annual savings of 0.2 MEUR through these measures, on top of the previously announced savings target of 0.4 MEUR. According to Bioretec, its production capacity is still oversized relative to current demand. The targeted savings of 0.2 MEUR are quite limited within the company's overall cost structure, and the announcement does not lead to immediate changes in our forecasts. We will account for the decreasing cost level in our model in connection with the next update.
Production capacity was scaled up too early
The company already stated in November 2025 that investments made in production have proven to be oversized in relation to the actual development of the business. According to the company, the previous negotiations, which resulted in the redundancy of one person and the temporary layoff of five people, were not enough to adjust production to the current volume. In recent years, Bioretec has invested in scaling up its production, anticipating a faster ramp-up in sales of the RemeOs product family. As we have previously emphasized, the market for orthopedic implants is very conservative by nature, and the adoption of new innovations, such as bioabsorbable metal implants, by customers is slow. The company appears to be tightly adjusting its cost structure to match actual demand in order to protect the cash reserves recently raised through the share issue.
Login required
This content is only available for logged in users
Bioretec operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio includes, for example, implants for pediatric and adult orthopedics and other materials for bone and soft tissue injuries. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in the Nordic region.
Read more on company pageKey Estimate Figures18.05.
| 2025 | 26e | 27e | |
|---|---|---|---|
| Revenue | 3.5 | 5.1 | 7.9 |
| growth-% | -22.5 % | 45.6 % | 54.1 % |
| EBIT (adj.) | -8.7 | -7.1 | -5.5 |
| EBIT-% (adj.) | -246.6 % | -138.0 % | -69.6 % |
| EPS (adj.) | -0.31 | -0.01 | -0.00 |
| Dividend | 0.00 | 0.00 | 0.00 |
| Dividend % | |||
| P/E (adj.) | neg. | neg. | neg. |
| EV/EBITDA | neg. | neg. | neg. |
Forum discussions
